

# Nociceptin Receptor - Drugs In Development, 2021

<https://marketpublishers.com/r/ND8A8C51F261EN.html>

Date: July 2021

Pages: 58

Price: US\$ 3,500.00 (Single User License)

ID: ND8A8C51F261EN

## Abstracts

Nociceptin Receptor - Drugs In Development, 2021

### SUMMARY

According to the recently published report 'Nociceptin Receptor - Drugs In Development, 2021'; Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre%li%and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.

The report 'Nociceptin Receptor - Drugs In Development, 2021' outlays comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and

Discovery stages are 1, 4, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones and Undisclosed which include indications Pain, Overactive Bladder, Somatic Pain, Substance (Drug) Abuse, Addiction, Alcohol Addiction, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Dyskinesia, Fibromyalgia (Fibromyalgia Syndrome), Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Low Back Pain, Neuropathic Pain (Neuralgia), Osteoarthritis Pain, Peripheral Neuropathic Pain, Post-Operative Pain, Post-Traumatic Stress Disorder (PTSD) and Unspecified.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Overview

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development

Astraea Therapeutics LLC

Grunenthal GmbH

Imbrium Therapeutics LP

Recordati SpA

Trigemina Inc

Tris Pharma Inc

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles

AT-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cebranopadol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRT-6010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMB-115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize ORL1 for Acute Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REC-0438 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Nociceptin Receptor for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder -  
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TI-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Product Development Milestones

Featured News & Press Releases

Aug 28, 2020: Imbrium Therapeutics presents first data and describes novel mechanism of action for IMB-115, a potential first-in-class treatment for insomnia disorder, at 34th Annual Sleep Meeting

Oct 16, 2019: Imbrium Therapeutics announces first patient dosed in phase 2 study of potential first-in-class molecule for insomnia associated with Alcohol Cessation

Jun 25, 2019: Imbrium Therapeutics advances insomnia pipeline through initiation of a phase 2 study of potential first-in-class molecule for insomnia associated with alcohol cessation

Aug 29, 2018: Scientists take big step toward finding non-addictive pain killer

Sep 30, 2016: Grunenthal's cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain

Aug 09, 2016: NIH Grant Will Fund Development of Small Molecules for Post-Traumatic Stress Disorder

May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile

Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2021  
Number of Products under Development by Therapy Areas, 2021  
Number of Products under Development by Indication, 2021  
Number of Products under Development by Companies, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Number of Products under Investigation by Universities/Institutes, 2021  
Products under Investigation by Universities/Institutes, 2021  
Number of Products by Stage and Mechanism of Actions, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Pipeline by Astraea Therapeutics LLC, 2021  
Pipeline by Grunenthal GmbH, 2021  
Pipeline by Imbrium Therapeutics LP, 2021  
Pipeline by Recordati SpA, 2021  
Pipeline by Trigemina Inc, 2021  
Pipeline by Tris Pharma Inc, 2021  
Dormant Products, 2021  
Dormant Products, 2021 (Contd..1)  
Discontinued Products, 2021



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Nociceptin Receptor - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/ND8A8C51F261EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ND8A8C51F261EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970